The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: A long-term follow-up study

Endocrine Research

Volumn 39, Issue 4, 2014, Pages 189-193

  Daliri, Mahdi ^a   Abbaszadegan, Mohammad Reza ^b   Mehrabi Bahar, Mostafa ^a   Arabi, Azadeh ^b   Yadollahi, Mona ^b   Ghafari, Azar ^c   Taghehchian, Negin ^b   Zakavi, Seyed Rasoul ^c  

^a Emam Reza Hospital   (Iran)

^b AVICENNA RESEARCH INSTITUTE   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

BRAF^{V600E< sup>; Genetic; Mutation; Papillary cancer; Prognosis; Thyroid}

Indexed keywords

RADIOACTIVE IODINE; THYROGLOBULIN; B RAF KINASE; BRAF PROTEIN, HUMAN; GENETIC MARKER;

ADULT; ADVANCED CANCER; ARTICLE; BRAF V600E GENE; CANCER PROGNOSIS; CANCER REGRESSION; CANCER STAGING; DISTANT METASTASIS; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC MARKER; GROUPS BY AGE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; ONCOGENE; POLYMERASE CHAIN REACTION; RADIATION EXPOSURE; REOPERATION; SINGLE STRAND CONFORMATION POLYMORPHISM; THERAPY DELAY; THYROID CARCINOMA; THYROIDECTOMY; AGE; AMINO ACID SUBSTITUTION; BLOOD; CARCINOMA; CARCINOMA, PAPILLARY; ENZYMOLOGY; GENETIC ASSOCIATION; GENETICS; IRAN; METABOLISM; MIDDLE AGED; MUTATION; OUTPATIENT DEPARTMENT; PATHOLOGY; PROGNOSIS; RADIATION RESPONSE; THYROID GLAND; THYROID NEOPLASMS;

ADULT; AGE FACTORS; AMINO ACID SUBSTITUTION; CARCINOMA; CARCINOMA, PAPILLARY; FEMALE; FOLLOW-UP STUDIES; GENETIC ASSOCIATION STUDIES; GENETIC MARKERS; HUMANS; IRAN; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; OUTPATIENT CLINICS, HOSPITAL; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; THYROGLOBULIN; THYROID GLAND; THYROID NEOPLASMS;

EID: 84911477717     PISSN: 07435800     EISSN: 15324206     Source Type: Journal    
DOI: 10.3109/07435800.2013.879169     Document Type: Article

References (37)

1. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. J Am Med Assoc 2006;295:2164-7.
2. Leenhardt L, Grosclaude P, Cherie-Challine L. Increased incidence of thyroid carcinoma in france: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid 2004;14:1056-60.
3. Hughes DT, Haymart MR, Miller BS, et al. The most commonly occurring papillary thyroid cancer in the United States is now a microcarcinoma in a patient older than 45 years. Thyroid 2011;21: 231-6.
4. Neuhold N, Schultheis A, Hermann M, et al. Incidental papillary microcarcinoma of the thyroid-further evidence of a very low malignant potential: a retrospective clinicopathological study with up to 30 years of follow-up. Ann Surg Oncol 2011;18:3430-6.
5. Page C, Biet A, Boute P, et al. 'Aggressive papillary' thyroid microcarcinoma. Eur Arch Otorhinolaryngol 2009;266:1959-63.
6. MacCorkle RA, Tan T-H. Mitogen-activated protein kinases in cell-cycle control. Cell Biochem Biophys 2005;43:451-61.
7. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007; 28:742-62.
8. Ciampi R, Nikiforov YE. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology 2007;148: 936-41.
9. Nikiforova MN, Nikiforov YE. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn 2008;8:83-95.
10. Kim SK, Kim D-L, Han HS, et al. Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules. Diagn Mol Pathol 2008;17:118-25.
11. Fugazzola L, Puxeddu E, Avenia N, et al. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 2006;13: 455-64.
12. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
13. Finkelstein A, Levy GH, Hui P, et al. Papillary thyroid carcinomas with and without BRAF V600E mutations are morphologically distinct. Histopathology 2012;60:1052-9.
14. Fugazzola L, Mannavola D, Cirello V, et al. BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol 2004;61:239-43.
15. Lee JH, Lee E-S, Kim Y-S. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer 2007;110:38-46.
16. Li C, Lee KC, Schneider EB, et al. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab 2012;97:4559-70.
17. Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 2013;309:1493-501.
18. Kim TY, Kim WB, Rhee YS, et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol 2006; 65:364-8.
19. Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005;90:6373-9.
20. Paterson IC, Greenlee R, Adams Jones D. Thyroid cancer in Wales 1985-1996: a cancer registry-based study. Clin Oncol (R Coll Radiol) 1999;11:245-51.
21. LiVolsi VA, Fadda G, Baloch ZW. Prognostic factors in welldifferentiated thyroid cancer. Rays 2000;25:163-75.
22. Sherman SI, Brierley JD, Sperling M, et al. Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 1998;83:1012-21.
23. Schlumberger M, Baudin E, Travagli JP. Papillary and follicular cancer of the thyroid. Cancers papillaire et vesiculaire de la thyroide 1998;27:1479-81.
24. Ranjbari N, Almasi S, Mohammadi-Asl J, et al. BRAF mutations in Iranian patients with papillary thyroid carcinoma. Asian Pac J Cancer Prev 2013;14:2521-3.
25. Puxeddu E, Moretti S. Clinical prognosis in BRAF-Mutated PTC. Arq Bras Endocrinol Metabol 2007;51:736-47.
26. Xu X, Quiros RM, Gattuso P, et al. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 2003;63:4561-7.
27. Kumagai A, Namba H, Saenko VA, et al. Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas. J Clin Endocrinol Metab 2004;89:4280-4.
28. Penko K, Livezey J, Fenton C, et al. BRAF mutations are uncommon in papillary thyroid cancer of young patients. Thyroid 2005;15:320-5.
29. D'Avanzo A, Ituarte P, Treseler P, et al. Prognostic scoring systems in patients with follicular thyroid cancer: a comparison of different staging systems in predicting the patient outcome. Thyroid 2004; 14:453-8.
30. Elisei R, Ugolini C, Viola D, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab 2008;93: 3943-9.
31. Voutilainen PE, Siironen P, Franssila KO, et al. AMES, MACIS and TNM prognostic classifications in papillary thyroid carcinoma. Anticancer Res 2003;23:4283-8.
32. Cushing SL, Palme CE, Audet N, et al. Prognostic factors in well-differentiated thyroid carcinoma. Laryngoscope 2004;114: 2110-5.
33. Elisei R, Molinaro E, Agate L, et al. Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. J Clin Endocrinol Metab 2010;95:1516-27.
34. Lupi C, Giannini R, Ugolini C, et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 2007;92:4085-90.
35. Lima J, Trovisco V, Soares P, et al. BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. J Clin Endocrinol Metab 2004;89:4267-71.
36. Hamatani K, Eguchi H, Ito R, et al. RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose. Cancer Res 2008; 68:7176-82.
37. Kebebew E, Weng J, Bauer J, et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 2007;246; 466-470; discussion 470-61.